The organisation has published a draft guidance rejecting the drug in combination with MabThera (rituximab) and bendamustine, for patients whose disease has relapsed or not responded to primary treatment and who cannot have a haematopoietic stem cell transplant.
The decision was made despite clinical trial evidence showing that the cancer became undetectable in around 40% of patients treated with Polivy, MabThera and bendamustine, compared with around 18% of patients treated with MabThera and bendamustine alone…
